NLS Pharmaceutics (NLSP) Competitors $1.80 -0.04 (-2.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.89 +0.09 (+5.00%) As of 08/1/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NLSP vs. PMN, CLNN, FGEN, NRSN, JATT, SCYX, CING, NNVC, QTTB, and TENXShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Promis Neurosciences (PMN), Clene (CLNN), FibroGen (FGEN), NeuroSense Therapeutics (NRSN), JATT Acquisition (JATT), SCYNEXIS (SCYX), Cingulate (CING), NanoViricides (NNVC), Q32 Bio (QTTB), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Its Competitors Promis Neurosciences Clene FibroGen NeuroSense Therapeutics JATT Acquisition SCYNEXIS Cingulate NanoViricides Q32 Bio Tenax Therapeutics Promis Neurosciences (NASDAQ:PMN) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings. Is PMN or NLSP more profitable? NLS Pharmaceutics' return on equity of 0.00% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Promis NeurosciencesN/A -186.19% -98.56% NLS Pharmaceutics N/A N/A N/A Which has higher valuation & earnings, PMN or NLSP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPromis NeurosciencesN/AN/A$2.78M-$0.05-15.33NLS PharmaceuticsN/AN/A-$1.98MN/AN/A Do analysts recommend PMN or NLSP? Promis Neurosciences currently has a consensus target price of $4.33, indicating a potential upside of 465.34%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Promis Neurosciences is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in PMN or NLSP? 50.1% of Promis Neurosciences shares are held by institutional investors. 6.1% of Promis Neurosciences shares are held by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to PMN or NLSP? In the previous week, Promis Neurosciences had 3 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for Promis Neurosciences and 0 mentions for NLS Pharmaceutics. Promis Neurosciences' average media sentiment score of 0.14 beat NLS Pharmaceutics' score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Promis Neurosciences Neutral NLS Pharmaceutics Neutral Which has more volatility and risk, PMN or NLSP? Promis Neurosciences has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500. SummaryPromis Neurosciences beats NLS Pharmaceutics on 7 of the 11 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.62M$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E RatioN/A8.9728.7823.81Price / SalesN/A437.65372.2066.04Price / CashN/A157.7635.4557.96Price / Book-4.864.838.275.54Net Income-$1.98M$31.62M$3.25B$259.28M7 Day Performance-9.09%-5.28%-3.70%-4.64%1 Month Performance-29.96%4.38%4.34%4.41%1 Year Performance718.18%-2.49%25.90%17.95% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$1.80-2.2%N/A+766.2%$6.62MN/A0.006Gap DownPMNPromis Neurosciences2.3779 of 5 stars$0.89-1.5%$4.33+388.5%-46.8%$29.00MN/A-17.745Upcoming EarningsShort Interest ↑Gap DownCLNNClene3.4949 of 5 stars$3.50-4.0%$40.00+1,041.6%-22.1%$28.97M$350K-0.87100Upcoming EarningsFGENFibroGen4.4046 of 5 stars$7.11-1.4%$250.00+3,418.2%-41.4%$28.71M$29.62M-2.84570Positive NewsUpcoming EarningsNRSNNeuroSense Therapeutics2.0763 of 5 stars$2.08+2.5%$14.00+573.1%+58.8%$28.43MN/A-3.8510News CoverageGap DownJATTJATT AcquisitionN/A$1.64-2.4%N/A-62.8%$28.29MN/A0.003Gap DownHigh Trading VolumeSCYXSCYNEXIS0.4576 of 5 stars$0.72-1.3%N/A-66.6%$28.21M$3.75M-1.2960Positive NewsUpcoming EarningsCINGCingulate3.0257 of 5 stars$5.34+2.2%$26.00+387.3%+1,408.9%$27.48MN/A-0.6320NNVCNanoViricides0.6653 of 5 stars$1.69-0.6%N/A-24.8%$27.16MN/A-2.3520Gap DownQTTBQ32 Bio1.4406 of 5 stars$2.22-0.5%$12.17+448.3%-94.7%$27.07MN/A-0.4539Upcoming EarningsShort Interest ↑TENXTenax Therapeutics1.3133 of 5 stars$6.22+2.7%$17.50+181.6%+94.4%$25.79MN/A-2.519Positive News Related Companies and Tools Related Companies Promis Neurosciences Alternatives Clene Alternatives FibroGen Alternatives NeuroSense Therapeutics Alternatives JATT Acquisition Alternatives SCYNEXIS Alternatives Cingulate Alternatives NanoViricides Alternatives Q32 Bio Alternatives Tenax Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLSP) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
